|
21 Apr 2020 |
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
|
|
20 Apr 2020 |
COVID-19: 155 drugs and 79 vaccines under development worldwide
|
|
17 Apr 2020 |
Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma A/S to Screen Novel VAP-1 Inhibitor Compounds for Inflammatory Skin Diseases
|
|
17 Apr 2020 |
LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
|
|
16 Apr 2020 |
Galapagos and Ryvu Announce Research Collaboration
|
|
15 Apr 2020 |
Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform
|
|
15 Apr 2020 |
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate
|
|
15 Apr 2020 |
TScan Announces Collaboration with Novartis on the Discovery and Development of Novel T Cell Receptor Therapies for the Treatment of Solid Tumors
|
|
14 Apr 2020 |
MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401
|
|
08 Apr 2020 |
Global COVID-19 Clinical Trial Tracker launched by Cytel
|
|
08 Apr 2020 |
Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform
|
|
07 Apr 2020 |
Beam Therapeutics Licenses SIRION Biotech’s LentiBOOST™ Technology for its CAR-T pipeline
|
|
06 Apr 2020 |
Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery
|
|
04 Apr 2020 |
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
|
|
04 Apr 2020 |
panCELLa Extends Exclusive License to Astellas
|
|
02 Apr 2020 |
Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma
|
|
02 Apr 2020 |
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
|
|
02 Apr 2020 |
Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa
|
|
02 Apr 2020 |
AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases
|
|
01 Apr 2020 |
Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of COVID-19
|
|
01 Apr 2020 |
Daiichi Sankyo Enters into Strategic Partnership with Ultragenyx for Use of Gene Therapy Manufacturing Technology
|
|
01 Apr 2020 |
REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder
|
|
01 Apr 2020 |
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines
|
|
27 Mar 2020 |
CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries
|
|
26 Mar 2020 |
ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing
|
